PDCD1 and plasma cell myeloma: The established myeloma-bearing mice were initially treated with lenalidomide (0.25 or 0.5 mg/kg), PD-1 blockade (250 μg/mouse), and dying myeloma cell-loaded DCs as a single therapy (Figure 1A).